Goldman Sachs downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a $9 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Strong Cash Position and Strategic Cost Reductions Drive Buy Rating and Increased Price Target
- Intellia Therapeutics price target raised to $14 from $12 at Citi
- Intellia Therapeutics price target lowered to $50 from $60 at Wells Fargo
- Intellia Therapeutics price target lowered to $26 from $55 at Barclays
- Intellia Therapeutics: Hold Rating Amid Long-Term Prospects and Strategic Restructuring